Immunome Inc. Income Statement
IMNM / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Immunome Inc. reported $7M in revenue and $212M in net loss for FY2025. Revenue has declined at a 29.6% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 4.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | - | - | - | - |
| SG&A Expense | $43.8M | $33.0M | $13.6M | $13.6M | $11.1M | $4.8M | $1.5M |
| R&D Expense | $177.3M | $129.5M | $23.3M | $23.3M | $14.1M | $7.5M | $8.8M |
| Operating Income | -$224.1M | -$305.8M | -$36.9M | -$36.9M | -$25.2M | -$12.3M | -$10.3M |
| Interest Expense | $11.7M | $12.8M | $5.0K | $5.0K | -$10.0K | -$38.0K | $46.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$212.4M | -$293.0M | -$36.9M | -$36.9M | -$24.7M | -$17.8M | -$10.4M |
| EPS (Basic) | -$2.43 | -$5.00 | -$3.09 | -$3.09 | -$2.14 | -$5.26 | - |
| EPS (Diluted) | -$2.43 | -$5.00 | -$3.09 | -$3.09 | -$2.14 | -$5.26 | - |
| Shares Outstanding | 113.1M | 64.5M | 12.1M | 12.1M | 11.5M | 3.4M | 1.1M |
| Operating Margin | -3228.8% | -3382.4% | -263.2% | - | - | - | - |
| Profit Margin | -3060.0% | -3240.4% | -263.2% | - | - | - | - |